Ceryvyn Therapeutics Ltd. - Unsponsored ADR
CYVNY Healthcare Biotechnology
Ceryvyn Therapeutics Ltd. - Unsponsored ADR’s revenue for fiscal 2025 (year ended June 2025) was $25,000.00, down 80.0% from fiscal 2024.
Follow CYVNY
Ceryvyn Therapeutics Ltd. - Unsponsored ADR (CYVNY) Altman Z-score
Ceryvyn Therapeutics Ltd. - Unsponsored ADR's Altman Z-score for fiscal 2025 is −30.38, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −30.38 | (23.87) |
| FY2024 | −6.51 | 1.75 |
| FY2023 | −8.26 | (12.62) |
| FY2022 | 4.36 | (55.71) |
| FY2021 | 60.06 | 5.37 |
| FY2020 | 54.70 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | (3.54) | — | −4.25 | |
| Retained earnings / total assets | (13.07) | — | −18.30 | |
| EBIT / total assets | (2.74) | — | −9.05 | |
| Market value of equity / total liabilities | 2.02 | — | 1.21 | |
| Sales / total assets | 0.00 | — | 0.00 | |
| Altman Z-score | Distress zone | −30.38 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −85.09 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| STTK Shattuck Labs, Inc. compare | 10.2× |
| CTMX CytomX Therapeutics, Inc. compare | 0.9× |
| VALN Valneva SE Sponsored ADR compare | −0.5× |
| PBYI Puma Biotechnology, Inc. compare | −4.2× |
| ACRS Aclaris Therapeutics, Inc. compare | −5.6× |
| CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR | −30.4× |
| FTH Faeth Therapeutics, Inc. compare | — |
| VECT VectivBio Holding AG compare | — |
| DRUG Bright Minds Biosciences Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets